Table 2 : Treatment responses after phase I and II of concurrent
chemoradiotherapy among group 1 (cisplatin treated patients) and
group II (cisplatin with paclitaxel treated patients).

	Group 1 N=25 (%)		Group II N=30 (%)
	Phase I	Phase II	Phase I	Phase II
CR	16 (64%)	20 (80%)	23 (76.7%)	26 (86.7%)
PR	5 (20%)	1 (4%)	5 (16.7%)	2 (6.7%)
SD and PD	4 (16%)	--	2 (6.7%)	--

CR: Complete response; PR: Partial response; SD: Stable disease;
PD: Progressive disease